CCNU (Lomustine)
From Glioblastoma Treatments
| Property | Information |
|---|---|
| Drug Name | CCNU (Lomustine) |
| FDA Approval | Yes |
| Used for | Glioblastoma |
| Clinical Trial Phase | Phase 3 (Germany) |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Hematological toxicity, nausea, vomiting, and pulmonary toxicity |
| OS without | Not specified |
| OS with | 23 months median survival, with 47% at 2 years |
| PFS without | Not specified |
| PFS with | Not specified |
| Usefulness Rating | 4 |
| Usefulness Explanation | Not specified |
| Toxicity Level | 4 |
| Toxicity Explanation | The toxicity level of CCNU is quite high due to several common side effects. Most notably, it can cause hematological toxicity, which means it can damage your blood cells and affect your body's ability to fight infections and clot properly. It can also cause nausea, vomiting, and pulmonary toxicity, which can lead to lung damage. On a scale from 1 to 5, with 5 being the most toxic, CCNU is rated as a 4. However, despite these side effects, the treatment showed promising results in a clinical trial. |
Notes: A combination of TMZ with CCNU showed promising results including a 5-year survival rate of 16% among a small patient cohort. MGMT methylation status significantly influenced outcomes.
From Ben Williams Book: Not specified
Loading comments...
